New Funding Rounds for 11 AI Pharmaceutical Companies in May

2024-06-04

蛋白降解靶向嵌合体

In May 2024, a total of 11 AI-driven pharmaceutical companies around the world raised new rounds of funding, amounting to approximately 2.021 billion Chinese yuan (about $290 million USD) in disclosed investments.

On the domestic front in China, two local AI pharma companies secured new funding. Shanghai-based Biaoxin Biotech raised funds in a Series A round, while Taizhou Xingputai Biotech received strategic investment worth tens of millions. Biaoxin, a spin-off from the Shanghai Institute of Immunochemistry, is developing oral protein degradation small molecule drugs using AI and machine learning models combined with high-throughput experimental data to guide drug design. The company currently has two molecular glue degrader drug candidates in clinical stages. Xingputai, founded by Shengpuze Tai in 2019, is a peptide-based new drug R&D company that integrates AI-powered drug discovery technology and green peptide synthesis.

Looking globally, the largest funding amount this month went to U.S. company Karius, which raised $100 million in a Series C round. Karius is using AI to disrupt traditional diagnostics, aiming to reduce the spread of antibiotic resistance by rapidly detecting pathogens from a single blood sample. Another early-stage U.S. startup, OverTBio founded by NYU professors, secured $16 million in a seed funding. OverTBio is a data-driven company developing gene-engineered immune cell therapies. Additionally, protein design startup NablaBio raised $26 million in Series A financing and announced strategic collaborations worth over $550 million with pharmaceutical giants AstraZeneca, Bristol Myers Squibb, and Takeda.

Across the Atlantic, the U.K.-based LabGenius, an AI-powered protein therapy developer, successfully closed a $44.51 million Series B round. Meanwhile, Hungary's Turbine, which uses AI to simulate cancer mechanisms and test potential drugs, also secured a new funding round.

This surge in AI pharma investments underscores the growing adoption of advanced technologies to drive innovation in drug discovery and development, with the potential to improve diagnostic capabilities and therapy options for patients.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构